TZD18
TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 228577-00-2
- 分子式: C27H27NO5S
- 分子量:477.57
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
hPPARα 0.028 μM (IC50) |
hPPARγ 0.057 μM (IC50) |
PPARδ >10 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-1 | EC50 |
>3 μM
Compound: 12
|
In vitro transactivation of human Peroxisome proliferator activated receptor delta measured in PPAR-GAL4 chimeric COS-1 cells
In vitro transactivation of human Peroxisome proliferator activated receptor delta measured in PPAR-GAL4 chimeric COS-1 cells
|
[PMID: 12873517] |
| COS-1 | EC50 |
0.014 μM
Compound: 12
|
In vitro transactivation of human peroxisome proliferator activated receptor gamma measured in PPAR-GAL4 chimeric COS-1 cells
In vitro transactivation of human peroxisome proliferator activated receptor gamma measured in PPAR-GAL4 chimeric COS-1 cells
|
[PMID: 12873517] |
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:12-13 weeks, Male db/db and nondiabetic db/+ (lean) mice (type 2 diabetes) [1]
-
Dosage:3, 10 mg/kg
-
Administration:P.o.; daily for 11 days
-
Result:Reduced hyperglycemia and plasma triglyceride levels.
化学情報
-
CAS 番号 228577-00-2
-
分子量 477.57
-
分子式 C27H27NO5S
-
SMILES
O=C(SC1C2=CC=CC(OCCCOC3=CC=C(C=C3CCC)OC4=CC=CC=C4)=C2)NC1=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)